<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221464</url>
  </required_header>
  <id_info>
    <org_study_id>PROICM 2019-01 BCA</org_study_id>
    <nct_id>NCT04221464</nct_id>
  </id_info>
  <brief_title>Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)</brief_title>
  <acronym>BCB</acronym>
  <official_title>Development of a Clinical and Biological Database Monocentric and Prospectivein Peritoneal Carcinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis
      must therefore be able to serve as a support for this essential search for transfer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to improve the knowledge of carcinocis mechanisms to develop a specific
      treatment.

      That's why this blood collection and tissue collection is very important for the future,
      these collection will be permitted to the scientists to develop a research specially for
      carcinosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">November 2029</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who gave their consent to participate in the study</measure>
    <time_frame>Until the study completion: 4 years</time_frame>
    <description>The proportion of patients who consent to participate in the study among the screened patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cancer</condition>
  <condition>Peritoneal Carcinosis</condition>
  <arm_group>
    <arm_group_label>Tumors and blood collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For all the patients include in the study :
Blood samples will be collected at different times : before any treatment, at every surgery, one month after any surgery, at progression.
Tumours and not tumours tissues will be collected at different times : Before any surgery, one month after any surgery
In parallel to this biological collection, standardized clinical data will be entered into a database treatment, at every surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biological collection</intervention_name>
    <description>Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression</description>
    <arm_group_label>Tumors and blood collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tissues collections</intervention_name>
    <description>Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression</description>
    <arm_group_label>Tumors and blood collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over the age of 18;

          -  Patient managed for peritoneal carcinosis : digestives origins (pancreatic,
             esogastric, colorectal, bowel) or peritoneum cancer

          -  Patient eligible for a peritoneal carcinosis treatment : at least one (or more)
             surgery (s) ;chemotherapy or any treatment for this disease

          -  Patient agree will all study procedure : biological samples &amp; tissues samples

          -  Patient giving informed consent

        Exclusion Criteria:

          -  Patient not affiliated to Social Protection system

          -  Patient unable to understand or comply with study instructions or requirements for
             psychological, family, social or geographical reasons

          -  The level of French is insufficient to consent to the study and to response to the
             questionnaires

          -  Patient under guardianship

          -  Pregnacy ou breast-feeding women

          -  Patient treated in case of an emergency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>QUENET François,MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut régional du cancer de Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BLEUSE Jean-Pierre,MD</last_name>
    <phone>467613100</phone>
    <phone_ext>33</phone_ext>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut du cancer de Montpellier ICM</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QUENET François,MD</last_name>
      <phone>0467612354</phone>
      <phone_ext>33</phone_ext>
      <email>francois.quenet@icm.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

